Johns Hopkins University

  • CTSA Program Hub
    Institute for Clinical and Translational Research
  • Event
    CD2H-teal
    Date
    -
    Healthcare Open Terminology (HOT) Ecosystem Community Webinar
  • Consortium News
    Logo for the COVID-19 Collaboration Platform
    Researchers can join forces with COVID-19 Collaboration Platform
  • This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.

    Whether 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course, can reduce severity of COVID-19 illness and/or improve time to recovery when compared with placebo.
    Target Population
    Inclusion Criteria:

    Admitted to a hospital with symptoms suggestive of COVID-19 infection.
    Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
    Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
    Male or non-pregnant female adult > / = 18 years of age at time of enrollment.
    Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:

    PCR positive in sample collected < 72 hours prior to randomization; OR
    PCR positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.
    Illness of any duration, and at least one of the following:

    Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
    SpO2 < / = 94% on room air, OR
    Requiring supplemental oxygen, OR
    Requiring mechanical ventilation.
    Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.
    Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.
    Exclusion Criteria:

    Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal.
    Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).
    Pregnancy or breast feeding.
    Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.
    Allergy to any study medication.
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    ClinicalTrials.gov Identifier
    NCT04280705
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 3
    Clinical Trial Network Utilization
    Yes
    Vaccine Trial Evaluation Unit
    Accrual Target Number
    572
    CTSA Support
    No
  • Resource
    Mapping 2019-nCoV Dashboard Snapshot
    Mapping 2019-nCov
  • Consortium News
    Practical Uses for Artificial Intelligence in Health Care
  • Event
    Trends in Research Flyer
    Date
    -
    5th Annual Trends in Clinical Research Symposium March 12
  • Networks
    Drawing of a network on a global
    SPIRiT Consortium
  • Consortium News
    Heartbeat EKG
    HIV Infection May Raise The Risk For Sudden Cardiac Death
  • Consortium News
    JH All Children's Hospital Logo
    Neil Goldenberg MD, director of All Children’s Hospital ICTR, Completes Kids-DoTT Study, The Largest Trial Ever Conducted in Pediatric Thromboembolism
  • Consortium News
    Study Shows Artificial Intelligence Can Detect Language Problems Tied to Liver Failure
  • Consortium News
    Pilot Award Recipient Chad Gordon Granted US Patent for System Designed to Assist with Facial Transplant Surgery
  • Consortium News
    JHU ICTR
    Deep Brain Stimulation Eases Parkinson’s Disease Symptoms by Boosting Dopamine
  • Event
    Henrietta Lacks Memorial Lecture 2019 Poster
    Date
    -
    Henrietta Lacks Memorial Lecture
  • Educational Content
    Johns Hopkins University Logo
    Data and Safety Monitoring Board Training Manual for Investigator-Initiated Studies
    Johns Hopkins University
  • Event
    Date
    -
    CD2H Federated Data Query Workshop
  • Event
    Date
    -
    Trial Innovation Network - FORMS-E: The New Application Package for Human Subjects and Clinical Trials
  • Opportunity

    Applications of Innovative Methods in Health Equity Research: Health, Behavior, and Society Summer Institute

    Employer/Host
  • Consortium News
    Data and Safety Monitoring Board Training Manual Now Available